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Summary Statement for Session (1) 
on In Vivo and In Vitro Testing of ALG 
E.M. LANCE 
In vivo testing 
From the data presented at this meeting it 
appears that most species of Macaques monkeys 
are suitable for demonstrating the immuno-
suppressive potency of anti human lymphocyte 
sera. Some of the subspecies appear to be more 
sensitive, such as the rhesus and speciosa, while 
Patas monkeys appear to be refractory. Some 
evidence suggests that baboons and cynomolgus 
monkeys are slightly less sensitive when used 
for this purpose. 
The evidence that the results of assays in mon-
keys and immunosuppressive potency in man 
are related remains at this time circumstantial 
and there is no conclusive proof that these 
assays are predictive for man. Even if they are 
predictive we do not yet know whether there 
will be direct proportionality between potency 
in monkeys and potency in man. 
There are a number of problems with the mon-
key, or surrogate assay as it is currently being 
performed. These include the lack of stand-
ardization amongst the various testing facilities 
particularly with respect to the species of 
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monkey used, the number of animals employed 
in screening for anyone antiserum, and the 
treatment schedules. These differences create 
difficulties in attempting to make cross com-
parisons from laboratory to laboratory. 
Apart from revealing potency, in vivo testing 
in monkeys can be used to detect toxicity. 
Acute systemic toxicity, hemolysis and throm-
bopenia as well as nephrotoxicity may be 
revealed and are probably predictive of nox-
ious antibody classes. There are in addition 
some adverse reactions which have been ob-
served in subhuman primates the mechanism 
of which is poorly understood. It is clear that 
intravenous administration is sometimes lethal 
and this may be in part explained by the phe-
nomenon of reversed anaphylaxis. Therefore, 
screening in subhuman primates for toxicity is a 
valuable safeguard prior to clinical application. 
In the future it would be highly desirable for 
the various facilities which are conducting this 
sort of test on a large scale to standardize their 
techniques. This standardization should apply 
to all the variables such as species, dosage 
schedule, the number of animals used for each 
antiserum, as well as the number of skin grafts 
applied to each monkey. In this way only will 
it be possible to define antisera in units of 
potency which will be comparable throughout 
the world. This in turn will make the inter-
pretation of clinical trials more meaningful. 
In vitro assays 
All of the various test systems which were 
described at this meeting gave a good corre-
lation within a species. That is, a high titer in 
the various tests usually was predictive of skin 
allograft prolongation in the appropriate ex-
perimental animal. Again these tests when 
used to titer anti human ALG showed a sta-
tistically significant correlation with the re-
sults of the surrogate host assay. However, 
some tests which were not discussed at this 
meeting such as opsonisation have also been 
reported to show a significant correlation. 
Moreover, there appears to be a good correla-
tion between the titers obtained in one in vitro 
assay system with those obtained in another. 
A difficulty that arises is that the product 
which is submitted to testing in the various 
laboratories is quite different. Some people 
use whole antiserum, others only IgG. The 
type and amount of absorption prior to testing 
varies from laboratory to laboratory and these 
factors create problems when one attempts 
cross-comparison from test to test. We believe 
it is highly desirable for in vitro testing to be 
confined to the product which is likely to be 
used in man, i. e. highly purified IgG which 
has been absorbed to remove noxious antibody 
classes. 
It is not possible at this stage to select any 
single test that possesses virtues which exceed 
that of any other. This will only become pos-
sible when reference sera have been tested in 
man and crosscorrelated with the various in 
vitro assays. At the moment it is probably 
sound policy to employ a battery of these tests. 
There may be safety in numbers and those 
assays which have at least the advantage of 
simplicity so that they can be applied by most 
laboratories appear to be rosette inhibition, 
indirect immunofluorescence, microcomplement 
fixation, indirect passive hemagglutination, and 
the cytotoxicity assay. 
Summary Statement for Session (2) 
Regarding Production and Purification 
H. BALNER 
Species 
It has been shown to be possible to raise ef-
fective ALG in numerous mammalian species: 
The horse is still most widely used but in view 
of the possibility of anaphylaxis, the avail-
ability of ALS raised in a not closely related 
species such as the rabbit is recommended. 
However, rabbit ALG should be used care-
fully in bone marrow transplantation since it 
may be damaging to hemopoietic stem cells. 
Furthermore, goat anti-human globulins were 
shown to be effective and remarkably devoid 
of toxic side effects. 
Antigen 
There is still a rather wide choice of eligible 
sources of human lymphoid antigen. Some 
antigen sources such as spleen and blood lym-
phocytes should be excluded mainly because it 
is difficult to remove contaminants leading to 
toxic, undesirable antibodies. 
Thoracic duct cells seem to be an excellent 
antigen but not easy to obtain. 
Thymocytes are widely and successfully em-
ployed but stromal elements should be carefully 
removed to avoid formation of GBM-reactive 
antibodies. 
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Cultured lymphoblasts have the advantage of 
constant quality and availability within a par-
ticular line. However, the characteristics (and 
content of relevant antigens) may differ from 
line to line and viral contamination may be 
a hazard. 
In contrast to impressions gained at previous 
ALS conferences the efficacy of antilymphoblast 
sera seems less consistent than that of anti-
thymocyte sera although methods to evaluate 
efficacy are obviously imperfect. 
As yet, insufficient data are available regarding 
optimal methods of storing cellular antigens. 
Membrane preparations have been used success-
fully. They offer the advantage of uniformity, 
easy storage and, most importantly, the pos-
sibility to select the relevant and eliminate 
irrelevant antigens. However, further stand-
ardization is necessary to extract the optimal 
membrane fractions from human lymphoid 
cells. 
Production 
There are numerous acceptable immunization 
methods. While the i. v. "two-pulse" method 
is still used to raise ALG in small animals 
there is an increasing use of various adjuvant 
methods especially in larger animals. 
The importance of producing very large pools 
of uniform standardized material is once again 
emphasized. To achieve this aim, highly ration-
alized production methods are essential; selec-
tion and pooling of batches requires thorough 
and repeated in vitro and in vivo testing to 
ensure i. s. potency and lack of toxicity. 
Several purification methods can be used to 
extract the active globulins from crude serum. 
Agreement has been reached that the i. s. prin-
ciple resides in the IgG fraction. For horse 
sera a further restriction to certain subclasses 
can be made (in fact the electrophoretic ally 
slow Y2 fraction is usually optimal). 
The problem of long-term storage of ALG 
urgently needs further investigation. 
Summary Statement of Session (3) and (4): 
Kidney Transplantation 
A. P. MONACO: 
The following represents the summary pre-
pared by Dr. Pichlmayr and I on the clinical 
transplantation reports of ALG-therapy. 
13 series of clinical renal transplantation were 
presented utilizing ALG as adjunctive immuno-
suppressive therapy in association with con-
ventional therapy of Imuran, prednisone and, 
in one instance, cyclophosphamide. 
The potential effectiveness of ALG was ex-
amined in 8 areas: 
1. Overall Survival Rates 
There was no clearcut demonstration that ALG 
improved one or two year overall-survival of 
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kidney and/or patients. At least 3 concurrent 
series with non-ALG controls failed to show 
an increase in overall survival. On the other 
hand, one and possibly two retrospective series 
clearly showed a definite increase in one year 
patient and kidney survival. 
2. Quality of Function of Surviving Grafts 
The point seems to be reasonably well estab-
lished by several series, particularly the con-
current series, that surviving ALG-patients 
show better renal function at one year (as de-
termined by creatinine clearance and serum 
creatinine levels) over surviving non-ALG-
treated patients. 
3. Levels of Steroids Required for 
Kidney Survival 
A very likely salutary effect of ALG is a de-
crease in the steroid requirement for main-
tenance of renal function in surviving patients. 
Furthermore, at least one series demonstrated 
a concomitant reduction of complications asso-
ciated with steroids in surviving patients treat-
ed with ALG. 
4. Incidence and Severity of the 
Rejection Reactions 
The majority of the ALG-treated series both 
with concurrent and retrospective controls de-
monstrated a definite and highly significant 
fall in the incidence of post-transplantation 
rejection reactions. Thus, there were in the 
order of 1,5 rejection reactions per patient per 
year in non-ALG recipients versus 0,5 rejec-
tions reactions per patient per year in ALG 
recipients. Furthermore, all agree that the se-
verity of the rejection reactions, when they did 
occur, was much less as measured by ease of 
reversal, the time required to return creatinine 
to normal levels, and the necessity for return 
to dialysis. Finally, many speakers on this point 
suggested that the overall general management 
of the patients was much easier in the ALG 
groups in terms of length of hospital stay etc. 
5. Use of ALG in the Treatment 
of Rejection Reactions 
One series which failed to demonstrate an 
overall salutary effect of ALG to improve 
survival rates of kidney and/or patients noted 
an almost unusual effectiveness of ALG 111 
treatment of rejection reactions. They were so 
impressed that they regarded use of ALG to 
be primarily for rejection treatment. Another 
series suggested a modest good effect of ALG 
in the rejection treatment but emphasized that 
best effectiveness was achieved when steroids 
were raised concurrently. However, the major-
ity of series failed to state, imply, or support 
the effectiveness in rejection reactions. 
18 Behring Inst. Mitt., 51 (1972) 
6. Effectiveness in Sensitized Patients and 
Second-Transplant Patients 
Several series reported results which suggested 
that the use of ALG in presensitized patients, 
i. e. crossmatch negative donor-recipient pairs, 
but recipients containing antibodies to a nor-
mal lymphocyte panel, failed to improve re-
sults in these potentially more difficult pa-
tients. On the other hand, one large controlled 
concurrent series considered the results of 
presensitized and second-transplant recipients 
better when given ALG and they proposed 
that this group of patients comprised an area 
where ALG was definitely indicated for 
therapy. 
7. Dose Effect 
With regard to differences of doses, at least 
two large series were able to show that higher 
doses of ALG on a mg/kg basis were preferable 
to lower doses. On the other hand when these 
two higher dose series are analyzed their over-
all survival rates were no better than any 
other series using somewhat lower doses. This 
apparently reflects differences in ALG potency. 
8. Substitution for Other Drugs 
No series reported regular substitution of ALG 
for one or more of the conventional immuno-
suppressive drugs. Several instances were cited, 
however, where one conventional drug could 
be removed, because of various emergencies and 
kidney function maintained in ALG-treated 
patients. 
The potential harmfulness of ALG therapy was 
evaluated in five problem areas: 
1. Survival Rates 
Fortunately, no series reported a decrease in 
either patient or kidney survival in ALG-
treated patients. 
2. Infections 
No series reported a clearcut increase in in-
fections in ALG-patients although several im-
plied that this might be true. 
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On the other hand it must be emphasized that 
clearcut reductions in rejection reactions with-
out obvious increase in one and two years 
survival suggested some negative effect might 
be operative and this might be in the area of 
serious or fatal infections. 
3. Direct Damage to Kidney Transplants 
Several instances were cited where kidneys 
were damaged by anti-GBM-antibody con-
tained in ALG. The majority of series, how-
ever, failed to consider this a significant dan-
ger and failed to show evidence of significant 
anti-kidney effect from ALG. 
4. Tumors 
No increased incidence III tumors were cited 
by any series. 
Summary of Session (8): 
Tumor Progression Risk 
D. w. van BEKKUM 
1. There is overwhelming evidence both in 
animals and man that tumor incidence in-
creased under continued immunosuppressive 
treatment. 
2. There is no evidence that this is a specific 
property of ALG. More experimental work 
is required to exclude the possibility that 
the administration of foreign proteins might 
predispose for certain tumor types such as 
lymphosarcomas. Careful retrospective an-
alysis of human cases, including the study 
of their complete immunosuppressive his-
tory, remains necessary. In experimental 
animals in most cases ALS was given alone. 
It is probably more relevant to include in 
future studies combination regimens, as are 
employed in clinical work. Controls for 
non-specific factors, that is, groups not re-
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5. Economic Problems and Cost 
The cost of ALG-production in certain in-
stances was definitely cited as a significant 
deterrent for its routine usage relative to the 
demonstrable benefit which could be attributed 
to it. 
Finally, in terms of future prospects, in the 
panel discussion, all agreed that ALG seemed 
to be beneficial particular in terms of rejection 
reactions. There seemed to be an overall im-
pression, however, which was explained and 
somewhat disappointing, that overall-one-year 
survival results had not been improved. Finally, 
I think it was the majority of opinions that 
more concurrent-controlled studies should be 
done. 
celvlllg oncogenic stimulation but only im-
munosuppressive agents, should more often 
be included. Finally, the possible causative 
role of the underlying diseases, genetical 
constitution etc., have to be kept in mind 
and for this the group of patients that re-
ceived kidneys from identical twins and 
have not received immunosuppressive ther-
apy are particularly suited as "controls". 
Maybe this group which is not so closely 
subjected to follow-up should be given spe-
cial attention. 
3. More experimental information is needed 
on the intrinsic oncogenic properties of con-
ventional immunosuppressive agents, such as 
Imuran, and even the steroids which, among 
others, kill lymphocytes, should be more 
carefully studied in this respect. 
4. As to the theoretical aspects of the mech-
anisms underlying carcinogenesis, these are 
changing rapidly. The concepts concerning 
immunological surveillance are being mod-
ified accordingly. If we want to establish 
the significance of the immune system by 
using long-term immunosuppressive regi-
mens, we should request that the animals 
are being monitored for their degree of im-
munosuppression, preferably during the 
whole study. This is now being recognized 
by most workers, but further perfectioning 
of suitable techniques is necessary in order 
to make this possible. 
In studies of surveillance mechanisms, more 
careful distinction should be attempted be-
tween increased susceptibility to infection 
by viruses - oncogenic or other - and de-
Summary of Session (9): 
creased defense against tumor specific anti-
gens. 
5. There IS conflicting clinical information 
about the influence of continued immuno-
suppression on tumor progression and on 
metastases-formation. Here the experimen-
tal evidence clearly indicates that one de-
terminative factor is the antigenicity of the 
tumor, and all we can recommend therefore, 
is that the fullest information on this prop-
erty be collected on all cancer cases. This 
group of patients constitutes an extremely 
valuable reservoir of information on human 
cancer biology and it is strongly recommend-
ed to Cancer Agencies to provide funds 
to transplantation biologists and immun-
ologists to exploit this reservoir of informa-
tion to the fullest. 
Tolerance and Enhancement in Relation to Use of ALG 
P. B. MEDAWAR 
There is solid and voluminous evidence from 
small laboratory animals that ALG can be 
used to promote tolerance when used in com-
bination with antigen. But more important, 
there is also convincing evidence that ALG can 
be used to promote tolerance in those larger 
experimental animals that are widely accepted 
as faithful models of human reactivity, I mean 
dogs and subhuman primates. On the contro-
versial question of relationship with tolerance 
and enhancement various views which question, 
vanous degrees of conviction, but it can't be 
said that any final conclusion was come to. 
I think it was generally agreed that the incep-
tion of tolerance remains an ambition for all 
organ transplantation with all immunosup-
pressive agents but no one propounded a meth-
od applicable to man by which this ambition 
could be achieved. In that respect this parti-
cular session did not come to a firm single 
conclusion. 
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Summary of the Bad Soden ALG-Workshop 
T. E. STARZL 
It was disconcerting to realize from an earlier 
meeting in San Diego, California, last December, 
the extent to which many really central prac-
tical questions about ALG had yet to be an-
swered. Some of these questions have been at 
least partially clarified at this present con-
ference. 
Certainly, anti-human ALG is or can be im-
munosuppressive. In proper doses the expres-
sion of preexisting delayed hypersensitivity is 
prevented and skin graft survival is prolonged. 
ALG has apparently been a key factor in mak-
ing possible successful bone marrow trans-
plantation between HLA non-identical donors 
and recipients as reported by Schwarzenberg. 
It was probably also a major factor in another 
break-through achievement - that of skin ho-
motransplantation by Diethelm in a burned 
child who would almost certainly have died 
otherwise. 
I doubt if there is an appropriately informed 
responsible scientist in the world who does not 
concede that ALG is a potent immunosuppres-
sive agent in humans. But that is not the ques-
tion which perplexes clinicians interested in 
renal transplantation. Rather, the issue is 
whether or not ALG fills some unique role 
that cannot be equally well met by the clever 
manipulation of other agents such as steroids, 
azathioprine and cyclophosphamide. Opinions 
about this were varied. Testimony about the 
value of ALG in renal transplantation was 
given from 13 centers. Eight positive votes 
were cast, but 4 clinicians did not believe that 
their results were improved, and one European 
surgeon thought they were actually worsened. 
The only controlled study in cadaveric renal 
transplantation that has yet been performed 
was brought up to date by Dr. Ross Sheil of 
Australia. His patients, who received a 2 months 
course of goat ALG in addition to mainte-
nance therapy with azathioprine and pred-
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l11sone fared better than those who did not 
get globulin. However, the differences were not 
overwhelming. Consequently, this small series, 
important and wisely planned as it was, must 
now have reinforcement. Although we our-
selves have resisted the compilation of a con-
trol series without ALG because of our con-
viction of the value of the globulin, I strongly 
support anyone who wishes to carry out such 
a controlled study and we will have to give 
consideration to this possibility ourselves. 
One reason why the question of indispensability 
of ALG must be settled is the tremendous in-
vestment of personal and material resources 
that have been required to make ALG avail-
able for human use. We heard examples in 
which the cost of ALG accounted for half the 
financial investment to treat a renal recipient. 
In addition, I am amazed at the amount of 
talent that is required to ensure a supply. These 
efforts and expenses will be worthwhile only if 
tangible and substantial benefits are demon-
strable. 
If such tangible benefits are not readily dis-
cernible in well controlled studies this side-
corner of transplantation is going to undergo 
acute atrophy. In addition to the nuisance of 
procuring it there are potential dangers with 
the administration of ALG. Anaphylaxis, which 
has led to several deaths, is the moot terrifying 
side effect, but there are others including in-
jection site pain, thrombocytopenia and injury 
to the homograft itself to mention only three. 
The Minnesota group has reported serious 
thrombotic complications with some high titer 
ALG which was given i. v. in their center and 
elsewhere. Apparently these thrombotic calami-
ties were caused by cross reactions of the anti-
white cell antibodies with recipient platelets. 
Of course, I do not know what the results of 
future controlled clinical trials will be but if as 
I suspect, they prove to be positive, it will be 
an enormous stimulus for companies like 
Behringwerke. Then the consumer cost would 
fall. In the long run the greatest market for 
commercial ALG might well be for patients 
with autoimmune disorders rather than for 
transplant recipients. The possibilities were dis-
cussed by Drs. Brendel, Piro/sky, and Traeger, 
who all emphasized the difficulty of evaluat-
ing the results in these disorders that so char-
acteristically undergo spontaneous remission 
and exacerbations. Sympathetic ophthalmia, 
from the reports we heard, may be an unusually 
specific indication for ALG treatment. In auto-
immune disorders, as in transplantation, ALG, 
if given without other potent immunosuppres-
sants may be excessively dangerous. 
Even if highly successful clinical transplanta-
tion trials are carried out, there will remain 
very major problems of standardization. It is 
not my responsibility to discuss these matters 
today, but I will mention four exceptionally 
sensitive points that must be clarified: first, the 
best animal in which to raise ALS, second, the 
most effective immunization schedule to be 
used, third, the correct antigen, and finally the 
in vitro and in vivo techniques for evaluating 
the effectiveness of the product. 
Personally, I doubt that the choice of animal is 
a crucial factor, a view supported by the studies 
of Simpson and of Barnes. The schedule of im-
munization is probably also not critical except 
that if the course is a short and standard one 
according to the M onaco-M edawar principle the 
ultimate product is apt to be relatively the 
same from animal to animal. In horses this was 
shown by Groth's data from 5 animals sub-
mitted to 3-pulse immunization with large 
numbers of lymphoblasts. 
The third question about the best antigen source 
is still open for discussion. The thymocyte has a 
number of advocates including Barnes, Kayhoe, 
Sheil, and Piro/sky. From the viewpoint of con-
venience and purity a contender is the cultured 
lymphoblast which as far as we know repre-
sents a pure B-cell population. There have been 
disquieting reports in the surrogate monkey 
system, from Kayhoe's laboratory, of a lack of 
a strong immunosuppressive effect in all anti-
lymphoblast sera studied so far by these 
workers. In contrast Seiler and BaIner have seen 
many strong anti-lymphoblast preparations, and 
of course the classical Minnesota dose-response 
curves in humans were derived with this kind 
of ALG. Consequently it is my guess that the 
lymphoblast will be the antigen of the future. 
Alternatively Lance made a strong case for 
stored lymphocyte cell membranes. 
Concerning the fourth point, there has been a 
gradual acceptance at least of at least 4 in vitro 
tests. Even a year ago there were flat denials 
that the leukoagglutinin and lymphocytotoxicity 
tests had any correlation with immunosuppres-
sive effect although it was commonly conceded 
that correlations were good with the Rosette 
inhibition test of Bach. Yet on Sunday of this 
meeting, Dr. Kayhoe told us that with rabbit 
ALG the cytotoxicity titers and potency in the 
monkey skin test system had an almost perfect 
correlation. In beautiful studies with the horse 
Seiler has as well as Johannsen shown that 
4 current titration methods all yielded about 
the same answer - cytotoxicity, lymphoagglu-
tination, rosette inhibition and micro-comple-
ment fixation - and that the heights of these 
titers were a relatively direct measure of the 
immunosuppressive quality as cross checked in 
the surrogate monkey model. Seiler pointed out 
that methodologic artifacts in measurement of 
anti-white cell titers may have accounted for 
discrepancies in the past. It was interesting that 
additional more or less new titration methods 
were described using indirect agglutination 
techniques both by Monaco and Revillard, and 
using an indirect immunofluorescence technique 
by Edwards. 
It may be superfluous to engage in much debate 
about the dose and administration schedules of 
such a poorly standardized agent as ALG. 
Nevertheless, it is important to attempt this by 
those who are or are planning to give ALG 
now. We have always believed that ALG for 
human use should have a minimum leuko-
agglutination and cytotoxicity titer of 1 :8000. 
We give adult patients ALG of this potency in 
volumes of 4-5 ml per injection intramuscu-
larly. Since the protein content of our material 
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is 5 mg % the dose per injection is approxi-
mately 4 to 5 mg/kg. It should be noted that 
this kind of dose in the Simmons dose-response 
curve caused an easily detectable prolongation 
of human skin graft survival. I am very much 
afraid that if these doses are further reduced 
either by using poor titer material or by de-
creasing the volume of injectate one may easily 
enter into homeopathic range. If alternating 
case studies of renal transplantation are carried 
out I hope that ALG will not be discredited 
by making this mistake of underdosage. It may 
be noted that Sheil takes strong account of his 
rosette inhibition titer in his dose scheduling. 
Traeger has also emphasized the need for ad-
equate dosage. 
The duration of ALG injections used together 
with a cytotoxic drug plus prednisone has 
ranged in clinical trial from 2 weeks to several 
months. How can we logically expect a lasting 
benefit in a human being from such a short 
therapeutic course. Sir Peter Medawar's session 
on tolerance, enhancement, and the popular 
notion of a combination of these factors pro-
moting graft acceptance have provided us with 
some speculative answers. In a crude way, it is 
appreciated that heavy early immunosuppression 
may promote graft acceptance by these means 
or by others not understood and that con-
Final Remarks 
H. G. SCHWICK 
Ladies and Gentlemen, our meeting is coming 
to the end. I hope that this workshop has been 
useful to everyone so that the long journeys 
were worthwhile. I think nobody was so opti-
mistic to assume that during this meeting all 
problems concerning ALG would be solved. 
But may be at least we approached to the 
solution. In any case the discussions have led 
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sequently the benefit of short but intense 
therapy with ALG may far outlast the actual 
time of treatment. There were reports from 
Monaco, Myburgh, Lance and Wilson about 
biologic "adjuvants" which might be used to 
facilitate graft acceptance at this critical early 
postoperative time. The techniques included the 
administration of tolerogenic antigens in the 
form of donor bone marrow or lymphoid cells 
or non-cellular extracts of lymphoid tissues 
along with or shortly after the transplantation 
of kidneys, livers, or whole limbs. Additively 
or alternatively, the evaluation of enhancing 
antibodies was described. 
In closing a very brief comment is in order 
about the development of malignancies in pa-
tients subjected to acute or chronic immuno-
suppression. There is no question that de novo 
malignancies occur in human recipients of renal 
homo grafts at an abnormally high incidence, 
although this complication by no means vitiates 
the value of the procedure. There is no time 
to dwell on this subject, beyond saying that the 
neoplasias are not associated especially with 
ALG, and that for reasons discussed yesterday 
by Medawar and his panel, having to do with 
the ability to reduce the level of chronic im-
munosuppression, the opposite may actually 
prove to be true. 
to an exchange in informations so far avail-
able and this is always the basis for progress 
111 SCIence. 
I like to thank all the chairmen who have led 
us through this extensive program. I like 
especially to thank my coworker Dr. Seiler who 
has done the whole organization work. 
I wish you a pleasant trip home. 
